UK-based Diurnal (AIM: DNL) has reached an agreement with Medison Pharma over the commercialization of Infacort (hydrocortisone) and Chronocort (hydrocortisone) in Israel.
Under the terms of the agreement, Medison will receive the exclusive rights to market and sell the treatments in Israel. Shares in Diurnal are up over 3% today.
Infacort, the first preparation of hydrocortisone designed for use in children suffering from adrenal insufficiency, was submitted for market authorization to the European Medicines Agency in late 2016.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze